Skip to main content
hello world

Provided Content: Content provided by Newswire.ca. The Globe and Mail was not involved, and material was not reviewed prior to publication.

Novavax Submits Application to Health Canada for Updated Protein-based 2024-2025 Formula COVID-19 Vaccine

Newswire.ca - Tue Jul 2, 7:30AM CDT

GAITHERSBURG, Md., July 2, 2024 /CNW/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, announced that it has filed for authorization with Health Canada for its 2024-2025 Formula COVID-19 vaccine (NVX-CoV2705) for individuals aged 12 and older. The submission follows the National Advisory Committee on Immunization (NACI) guidance to use the latest selected strain and the guidance from the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA) and World Health Organization (WHO).1-4 

Read more at newswire.ca